BSE Live
Nov 14, 16:01Prev. Close
1208.85
Open Price
1210.05
Bid Price (Qty.)
1225.00 (10)
Offer Price (Qty.)
1232.00 (30)
NSE Live
Nov 14, 15:59Prev. Close
1210.20
Open Price
1210.20
Bid Price (Qty.)
1222.50 (562)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Aurobindo Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 31.96 | 26.11 | 30.94 | 29.16 | 27.85 | |
| Diluted EPS (Rs.) | 31.96 | 26.11 | 30.94 | 29.16 | 27.85 | |
| Cash EPS (Rs.) | 39.99 | 33.16 | 37.00 | 34.01 | 32.29 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 222.32 | 193.73 | 170.38 | 143.99 | 117.32 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 222.32 | 193.73 | 170.38 | 143.99 | 117.32 | |
| Dividend / Share(Rs.) | 3.00 | 2.50 | 2.50 | 2.50 | 2.50 | |
| Revenue from Operations/Share (Rs.) | 226.43 | 209.21 | 175.28 | 163.97 | 156.63 | |
| PBDIT/Share (Rs.) | 52.72 | 44.52 | 46.95 | 42.84 | 45.12 | |
| PBIT/Share (Rs.) | 44.69 | 37.47 | 40.89 | 37.95 | 40.62 | |
| PBT/Share (Rs.) | 40.58 | 33.53 | 39.99 | 37.18 | 36.70 | |
| Net Profit/Share (Rs.) | 31.96 | 26.11 | 30.94 | 29.13 | 27.80 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 23.28 | 21.28 | 26.78 | 26.12 | 28.80 | |
| PBIT Margin (%) | 19.73 | 17.91 | 23.32 | 23.14 | 25.93 | |
| PBT Margin (%) | 17.92 | 16.02 | 22.81 | 22.67 | 23.43 | |
| Net Profit Margin (%) | 14.11 | 12.47 | 17.65 | 17.76 | 17.74 | |
| Return on Networth / Equity (%) | 14.37 | 13.47 | 18.15 | 20.23 | 23.69 | |
| Return on Capital Employed (%) | 19.87 | 19.25 | 23.86 | 25.92 | 32.91 | |
| Return on Assets (%) | 9.58 | 8.43 | 11.47 | 13.10 | 12.94 | |
| Total Debt/Equity (X) | 0.29 | 0.40 | 0.37 | 0.34 | 0.55 | |
| Asset Turnover Ratio (%) | 0.70 | 0.72 | 0.71 | 0.75 | 0.80 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.77 | 1.55 | 1.56 | 1.55 | 1.45 | |
| Quick Ratio (X) | 1.09 | 0.96 | 0.97 | 1.01 | 1.00 | |
| Inventory Turnover Ratio (X) | 1.63 | 1.75 | 1.67 | 1.89 | 1.93 | |
| Dividend Payout Ratio (NP) (%) | 9.38 | 9.57 | 12.12 | 6.68 | 8.26 | |
| Dividend Payout Ratio (CP) (%) | 7.50 | 7.53 | 10.13 | 5.72 | 7.11 | |
| Earnings Retention Ratio (%) | 90.62 | 90.43 | 87.88 | 93.32 | 91.74 | |
| Cash Earnings Retention Ratio (%) | 92.50 | 92.47 | 89.87 | 94.28 | 92.89 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 27,852.67 | 50,495.77 | 36,057.21 | 42,393.57 | 47,018.50 | |
| EV/Net Operating Revenue (X) | 2.10 | 4.12 | 3.51 | 4.41 | 5.13 | |
| EV/EBITDA (X) | 9.02 | 19.36 | 13.11 | 16.89 | 17.81 | |
| MarketCap/Net Operating Revenue (X) | 1.82 | 3.76 | 3.18 | 4.12 | 4.76 | |
| Retention Ratios (%) | 90.61 | 90.42 | 87.87 | 93.31 | 91.73 | |
| Price/BV (X) | 1.86 | 4.06 | 3.27 | 4.69 | 6.35 | |
| Price/Net Operating Revenue | 1.82 | 3.76 | 3.18 | 4.12 | 4.76 | |
| Earnings Yield | 0.08 | 0.03 | 0.06 | 0.04 | 0.04 |
14.11.2025
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
12.11.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL